User login
Key clinical point: Safety is the most valued treatment attribute for adults with moderate-to-severe atopic dermatitis (AD), followed by the mode of administration, whereas monitoring requirements is the least critical attribute.
Major finding: The risk for severe adverse events emerged as the most important attribute (coefficient 0.42; 95% CI 0.36-0.49), followed by the ease of treatment administration with daily oral pills vs biweekly injections (coefficient 0.41, 95% CI 0.35-0.48). Avoiding monitoring for severe adverse events was the least critical attribute (coefficient 0.02; 95% CI −0.03 to 0.07).
Study details: This study included 713 adults with moderate-to-severe AD having Patient-Oriented Eczema Measure scores > 7 or current or prior exposure to systemic treatment who completed the online discrete choice experiment survey for treatment preferences in AD.
Disclosures: This study was sponsored by LEO Pharma. Five authors declared being employees of LEO Pharma or EY Economics Denmark, a paid vendor of LEO Pharma. Some authors declared serving as advisors, consultants, etc., for or receiving research grants, etc., from LEO Pharma and others.
Source: Ameen M, Alhusayen R, Brandi H, et al. Patient preferences in the treatment of moderate-to-severe atopic dermatitis. Acta Derm Venereol. 2024 (Feb 21). doi: 10.2340/actadv.v104.19454 Source
Key clinical point: Safety is the most valued treatment attribute for adults with moderate-to-severe atopic dermatitis (AD), followed by the mode of administration, whereas monitoring requirements is the least critical attribute.
Major finding: The risk for severe adverse events emerged as the most important attribute (coefficient 0.42; 95% CI 0.36-0.49), followed by the ease of treatment administration with daily oral pills vs biweekly injections (coefficient 0.41, 95% CI 0.35-0.48). Avoiding monitoring for severe adverse events was the least critical attribute (coefficient 0.02; 95% CI −0.03 to 0.07).
Study details: This study included 713 adults with moderate-to-severe AD having Patient-Oriented Eczema Measure scores > 7 or current or prior exposure to systemic treatment who completed the online discrete choice experiment survey for treatment preferences in AD.
Disclosures: This study was sponsored by LEO Pharma. Five authors declared being employees of LEO Pharma or EY Economics Denmark, a paid vendor of LEO Pharma. Some authors declared serving as advisors, consultants, etc., for or receiving research grants, etc., from LEO Pharma and others.
Source: Ameen M, Alhusayen R, Brandi H, et al. Patient preferences in the treatment of moderate-to-severe atopic dermatitis. Acta Derm Venereol. 2024 (Feb 21). doi: 10.2340/actadv.v104.19454 Source
Key clinical point: Safety is the most valued treatment attribute for adults with moderate-to-severe atopic dermatitis (AD), followed by the mode of administration, whereas monitoring requirements is the least critical attribute.
Major finding: The risk for severe adverse events emerged as the most important attribute (coefficient 0.42; 95% CI 0.36-0.49), followed by the ease of treatment administration with daily oral pills vs biweekly injections (coefficient 0.41, 95% CI 0.35-0.48). Avoiding monitoring for severe adverse events was the least critical attribute (coefficient 0.02; 95% CI −0.03 to 0.07).
Study details: This study included 713 adults with moderate-to-severe AD having Patient-Oriented Eczema Measure scores > 7 or current or prior exposure to systemic treatment who completed the online discrete choice experiment survey for treatment preferences in AD.
Disclosures: This study was sponsored by LEO Pharma. Five authors declared being employees of LEO Pharma or EY Economics Denmark, a paid vendor of LEO Pharma. Some authors declared serving as advisors, consultants, etc., for or receiving research grants, etc., from LEO Pharma and others.
Source: Ameen M, Alhusayen R, Brandi H, et al. Patient preferences in the treatment of moderate-to-severe atopic dermatitis. Acta Derm Venereol. 2024 (Feb 21). doi: 10.2340/actadv.v104.19454 Source